RN7SL308P

Across TCGA pan-cancer cohorts, RN7SL308P RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated RN7SL308P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RN7SL308P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RN7SL308P expression acts as an unfavorable survival marker, although some lineages such as OV and SKCM show a favorable association.

LIHC, LUSC, and KIRC are the cancer types where RN7SL308P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.108	0.702	<.001	45	view →
LUSC	OS	Tertile	III,IV	0.011	0.684	<.001	36	view →
KIRC	DFS	Tertile	IV	0.243	0.518	.039	36	view →
ESCA	OS	Median	IV	0.222	0.698	.006	30	view →
KICH	OS	Tertile	III,IV	0.178	0.847	<.001	21	view →
LUAD	OS	Tertile	IV	0.153	0.714	.012	18	view →
OV	DFS	Tertile	All	0.198	0.143	.022	14	view →
UVM	OS	Tertile	All	0.365	0.734	.018	12	view →
GBM	DFS	Tertile	All	0.143	0.257	.037	9	view →
SKCM	OS	Tertile	All	0.517	0.297	.018	9	view →
READ	DFS	Tertile	II,III,IV	0.407	0.724	.046	9	view →
BRCA	OS	Tertile	III,IV	0.237	0.580	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

RN7SL308P–LIHC (OS)

Open the LIHC breakdown →